Background {#Sec1}
==========

It has been proposed that high consumption of meat, including red and processed meat as well as fish, confers risk of prostate cancer \[[@CR1]--[@CR5]\]. Heterocyclic aromatic amines (HAAs), which are known mutagens formed in cooked meat and fish at high temperatures, are considered the causative agents for the association between meat intake and prostate cancer risk \[[@CR2], [@CR6]--[@CR8]\].

HAAs can metabolically result in carcinogenesis through the formation of HAA-DNA adducts \[[@CR9]--[@CR11]\], which lead to tumor formation by conferring mutations in genes that control cell proliferation \[[@CR12]\]. In addition, it was shown that human prostate cells metabolize HAAs to a carcinogenic state by forming HAA-DNA adducts after exposure to HAAs in vivo \[[@CR8], [@CR13]--[@CR16]\].

Several studies have investigated whether there is an association between dietary HAA intake and prostate cancer risk; however, results were suggestive yet inconclusive \[[@CR1], [@CR3], [@CR17], [@CR18]\]. This disparity reflects two main reasons. First, it is difficult to assess dietary HAA intake, the composition of which varies according to the cooking method and meat type \[[@CR19], [@CR20]\]. In Japan, several studies investigated prostate cancer risk, using only meat and fish intake \[[@CR21], [@CR22]\]; however, no prior study has investigated the risk by estimating the dietary HAA intake. Typically, Japanese elderly people intake more fish than meat, and they prefer chopping and stir-frying their meat to grilling \[[@CR23], [@CR24]\]. Foods that contribute to HAA intake differ by country \[[@CR25]\]; therefore, dietary assessment tools for HAA intake should be tailored specifically to the population being studied.

The second reason is the difficulty in assessing a study population in terms of metabolic variation determined by genetic heterogeneity. Similar to other environmental chemical carcinogens, it is necessary for HAAs to be metabolically activated by host enzymes to acquire genetic toxicity. Phase I enzymes such as cytochrome P450 (CYP) enable HAAs to metabolically activate and, thus, form genotoxic electrophilic intermediates \[[@CR26]\]. This transition enables phase II enzymes, including *N*-acetyltransferase 1 (*NAT1*) and *N*-acetyltransferase 2 (*NAT2*), to detoxify part of the activated metabolites by performing the tasks of N-acetylation and O-acetylation \[[@CR27]\]. It is presumed that the relative activities of these metabolizing enzymes, which are mostly genetically determined, have a critical role in HAA-mediated prostate cancer development.

In the phase I cytochrome P450 family, *CYP1A1* and *CYP1A2* are highly active in the liver and play a major role in the metabolic activation of HAAs, and each enzyme activity has been considered to be linked to genetic variations \[[@CR18], [@CR28], [@CR29]\]. In phase II enzymes, previous studies suggested that the genetic polymorphisms in *NAT1* and/or *NAT2* may modify prostate cancer risk related to exposure to HAA carcinogens \[[@CR30]\]. The frequencies of *NAT1* and *NAT2* genotype varies according to racial and ethnic background, and the frequency difference may be a factor in cancer incidence \[[@CR31]\]. Although *NAT1* is expressed in the prostate, the relationship between the *NAT1* genotype and phenotype in a Japanese population remains unclear \[[@CR32]\]. On the other hand, *NAT2* is expressed predominantly in the liver, and the relationship between genetic variants of *NAT2* and the acetylator phenotype in Japanese individuals is clear \[[@CR31], [@CR33]--[@CR35]\]. It is considered that the *NAT2* slow acetylator phenotype would increase the prostate cancer risk because this phenotype would have reduced hepatic N-acetylation for detoxification of HAA carcinogens, thus increasing the chance of hepatic N-hydroxylation for activation \[[@CR36]\].

Therefore, in this study, we used a validated assessment food frequency questionnaire (FFQ) to assess dietary HAAs in Japanese cultural contexts \[[@CR25], [@CR37], [@CR38]\] and investigated the phenotypes and genotypes of *NAT2*, *CYP1A1*, and *CYP1A2* in our subjects. To the best of our knowledge, no prior reports have investigated the relationship between *NAT2*, *CYP1A1*, and *CYP1A2* polymorphisms and HAAs as risk factors for prostate cancer in a Japanese population. The purpose of this study was to determine the impact of HAA intake and genetic polymorphisms in *NAT2*, *CYP1A1*, and *CYP1A2* on prostate cancer in Japanese men.

Methods {#Sec2}
=======

Design {#Sec3}
------

This study was a secondary data analysis of an observational case control study. Written informed consent was obtained from all subjects by the return of the questionnaires. The study protocol received ethics approval by the institutional review board of Faculty of Life Sciences, Kumamoto University (Kumamoto, Japan), on June 10, 2016 (approval number 209). The first and last authors take all responsibility for the integrity of the data and the accuracy of the data analysis.

Subjects {#Sec4}
--------

We identified 750 eligible male patients between 40 to 90 years of age who were diagnosed with histologically confirmed prostate cancer at the Jikei University School of Medicine Hospital (Tokyo, Japan) from August 2004 to December 2006. We also identified 870 men as prospective controls in the same age range who (i) underwent comprehensive medical examination for health screening at the Mitsui Memorial Hospital (Tokyo, Japan) during the same survey period, (ii) exhibited no evidence of prostate cancer as determined by blood test (PSA \< 4 mg/dL), and (iii) provided consent for participation. Because age is a known risk factor for prostate cancer, we selected age-adjusted control subjects according to the average age of our affected group and identified 351 cases and 351 controls for analysis.

Exposure assessment {#Sec5}
-------------------

Subjects completed a self-administered questionnaire regarding general characteristics: age, sex, height, weight, occupation, smoking and drinking habits, dietary habits, personal medical history, and family history including prostate cancer. Food and beverage consumption was assessed with a food frequency questionnaire (FFQ) \[[@CR23]\] that consists of 138 food and beverage items, which asks to report the usual consumption of the listed foods during the past year. Frequency response choices for food items consisted of nine options: less than once per month, 1--3 times per month, 1--2 times per week, 3--4 times per week, 5--6 times per week, once per day, 2--3 times per day, 4--6 times per day, and 7 or more times per day. Further, standard portion sizes were selected for each food item with three choices: medium (standard), small (50% smaller), and large (50% larger).

HAA consumption is a different parameter in meat and fish consumption. For fish, HAA intake was estimated from 19 kinds of items: salted fish, semi-dried split fish, salmon, horse mackerel or sardines, Pacific saury or mackerel, and eel from six groups. In addition, participants were asked about grilled skin consumption using five quantity categories: almost none, one-third, half, two-thirds, and almost all. HAA intake from fish consumption was then estimated based on the proportion of grilled to total fish consumption, the rate of grilled skin consumption, the ratio of skin-to-flesh, and data on HAA content in the skin and flesh.

Similarly, HAA intake from meat was estimated according to 7 of 18 meat items: pan-fired and grilled beef, stir-fried pork and pork liver, grilled chicken and chicken liver, and bacon. Participants reported their preferred grilled level of pan-fried and grilled beef among five categories: very well-done, well-done, medium, medium rare, and rare. HAA intake consumption was then estimated based on this information and data on HAA content, which were validated measurements of 2-amino-1-methyl-6-phenylimidazo\[4,5-b\]pyridine (PhIP) levels in the hair from a prior study \[[@CR25], [@CR37], [@CR38]\].

Genotyping {#Sec6}
----------

Blood samples were obtained from all participants and collected during the protocol period before a procedure was performed. Buffy coats were preserved at − 80 °C soon after blood sampling until analysis. Pre-validated allelic discrimination TaqMan real-time PCR (Applied Biosystems, Foster City, CA, USA) was used for genotyping of single nucleotide polymorphisms (SNPs). The reaction solution (9 μL) was aliquoted into each well of a 48-well reaction plate, and 1 μL of DNA or water control was added to each tube.

*NAT2* slow acetylator alleles were reported as: *NAT2*\*5 (rs1801280: T \> C), *NAT2*\*6 (rs1799930: G \> A), and *NAT2*\*7 (rs1799931: G \> A). Although *NAT2*\*13 (rs1208: A \> G) was previously considered among slow acetylator alleles, recent studies have indicated that alleles of *NAT2*\*4 and *NAT2*\*13 dominantly determine the fast acetylator phenotype \[[@CR31]--[@CR35]\]. Slow acetylators were classified if individuals have at least two variant alleles, and intermediate acetylators were categorized as those individuals having one slow acetylator allele from these loci. Genotyping of rs1048943 (A \> G) at *CYP1A1* and rs762551 (A \> G) at *CYP1A2* was also undertaken.

Statistical analysis {#Sec7}
--------------------

For demographic and clinical data, we used the chi-square test to compare proportions of categorical variables and the Mann--Whitney test to compare the averages of continuous variables between groups. Conditional logistic regression models were used to evaluate the relationship between HAA intake and genotype. Our models were adjusted for variables associated with prostate cancer identified either by the current study or by previous studies \[[@CR39]--[@CR41]\] and included alcohol consumption, smoking status, body mass index (BMI), family history of prostate cancer, and total energy intake. Intake of HAA and other nutrients and foods was adjusted for total energy intake using the residual model \[[@CR42]\]. HAA intake was divided into tertile categories and evaluated using the Cochran--Armitage test for trend. To identify associations between HAA intake and polymorphisms of tested genes, we assessed HAA intake based on subgrouping subjects as "rapid/intermediate" or "slow" for *NAT2* as well as by variant alleles, and by those with two wild-type alleles for *CYP1A1* and *CYP1A2*. The threshold for significance was *P* \< 0.05. All statistical analyses were conducted using SPSS version 21 (IBM Corp., Armonk, NY, USA).

Results {#Sec8}
=======

The general characteristics of our cohorts are presented in Table [1](#Tab1){ref-type="table"}. This study included 351 patients with prostate cancer with a pathologically confirmed diagnosis and 351 cancer-free controls, aged from 50 to 79 years of age. The average age in both groups was 64.9 years. We observed that a significantly higher rate of family history of prostate cancer was found in cases compared to that in controls, while the rate of alcohol consumption was lower in cases compared to that in controls. Although we found no differences in BMI and total energy intake between the two groups, we found significantly higher rates of the following measures in cases compared to those in controls: total HAA intake; 3-amino-1, 4-dimethyl-5H-pyrido\[4, 3-b\]indole (Trp-P-1); 2-amino-3-methylimidazo\[4, 5-f\]quinoline (IQ); 2-amino-3, 4-dimethylimidazo\[4, 5-f\]quinoline (MeIQ); 2-amino-3, 8-dimethylimidazo\[4, 5-f\]quinoxaline (MeIQx); and PhIP. We found no statistically significant differences between cohorts for other variables including meat, red meat, processed meat, vegetable, and salt (NaCl) intake as well as the rate of those who prefer their meat well done or ate almost all burnt fish skin.Table 1Characteristics of cases and controlsCharacteristicsCasesControls*P*Number351351Age, years; mean (SD)64.9 (0.35)64.9 (0.35)1.00^b^ \< 65; *n* (%)180 (51.3%)180 (51.3%) ≥ 65; *n* (%)171 (48.7%)171 (48.7%)1.00^a^Family history of prostate cancer; *n* (%)13 (3.7%)4 (1.1%)0.027^a^Alcohol consumption, g/week; mean (SD)151.6 (192.4)196.0 (207.2)\< 0.001^b^Smoking status; *n* (%) Never126 (35.9%)108 (30.8%) Ever225 (64.1%)243 (69.2%)0.15^a^ Current smoker55 (15.7%)67 (19.1%)0.23^a^ Ex-smoker170 (48.4%)176 (50.1%)0.65^a^BMI, kg/m^2^; mean (SD)23.8 (0.14)23.8 (0.13)1.00^b^Total HAA intake, ng/day; mean (SD)46.5 (1.6)38.2 (1.7)\< 0.001^b^ Trp-P-1 intake3.9 (0.23)3.1 (0.19)\< 0.001^b^ IQ intake0.32 (0.021)0.27 (0.018)0.012^b^ MeIQ intake5.9 (0.21)4.8 (0.17)\< 0.001^b^ MeIQx intake6.4 (0.21)5.2 (0.20)\< 0.001^b^ 4,8-DiMelQx intake0.41 (0.34)0.36 (0.33)0.10^b^ 7,8-DiMelQx intake1.6 (0.14)1.4 (0.14)0.06^b^ PhIP intake28.2 (0.98)23.3 (0.93)\< 0.001 ^b^Total energy intake, kcal/day; mean (SD)1869.2 (567.8)1789.3 (519.9)0.30^b^Meat intake, g/day; mean (SD)59.9 (41.0)50.2 (36.1)0.84^b^Red meat intake, g/day; mean (SD)47.3 (33.8)37.6 (31.0)0.87^b^Processed meat intake, g/day; mean (SD)7.1 (7.9)6.3 (8.6)0.42^b^Fish intake, g/day; mean (SD)84.2 (58.3)77.4 (62.8)0.51^b^Vegetable intake, g/day; mean (SD)88.7 (68.4)82.7 (73.2)0.24^b^NaCl intake, g/day; mean (SD)10.1 (4.5)9.2 (4.1)0.79^b^Participants with preference on meat cooked level as well done or very well done (%)33 (50.7%)26(44%)0.40^a^Participants with preference on eating almost all of grilled fish skin (%)71 (50.4%)70 (49.6%)0.99^a^*BMI* body mass index; *SD* standard deviation; *HAA* heterocyclic aromatic amine; *NaCl* sodium chloride; *Trp-P-1* 3-Amino-1, 4-dimethyl-5H-pyrido\[4, 3-b\]indole; *IQ* 2-Amino-3-methylimidazo\[4,5-f\]quinoline; *MeIQ* 2-Amino-3,4-dimethylimidazo\[4,5-f\]quinoline; *MeIQx* 2-Amino-3,8-dimethylimidazo\[4,5-f\]quinoxaline; *4,8-DiMelQx* 2-Amino-3, 4, 8-trimethylimidazo\[4, 5-f\]quinoxaline; *7,8-DiMelQx* 2-Amino-3, 7, 8-trimethylimidazo\[4, 5-f\]quinoxaline; *PhIP* 2-Amino-1-methyl-6-phenylimidazo\[4,5-b\]pyridine^a^Chi-square test^b^Mann-Whitney test

As shown in Table [2](#Tab2){ref-type="table"}, the distribution of genotyped SNPs was *NAT2*\*5 (rs1801280), *NAT2*\*6 (rs1799930), *NAT2*\*7 (rs1799931), *NAT2*\*13 (rs1208), *CYP1A1* (rs1048943), and *CYP1A2* (rs762551). Genotype frequencies of each SNP were consistent with Hardy--Weinberg equilibrium among controls.Table 2SNPs and their allele frequencies in *NAT2*, *CYP1A1*, and *CYP1A2*SNP rs \#Amino acid changeMajor/minor alleleMajor allele frequency in control group*NAT2* NAT2\*5rs1801280Ile114ThrT/C0.986 NAT2\*6rs1799930Arg197GlnG/A0.96 NAT2\*7rs1799931Gly286GluG/A0.641 NAT2\*13rs1208Lys268ArgA/G0.826*CYP1A1*rs1048943Ile462ValA/G0.661*CYP1A2*rs7625515′-UTRA/C0.379*UTR* untranslated region, *SNP* single nucleotide polymorphism

Multivariate odds ratios (ORs) for HAA intake were analyzed, and several HAA-related measures with high intake were significantly associated with an increased risk of prostate cancer compared to controls (Table [3](#Tab3){ref-type="table"}): total HAA (OR, 1.90; 95% confidence interval (95% CI), 1.40--2.59), Trp-P-1 (OR, 1.92; 95% CI, 1.42--2.61), MeIQ (OR, 1.87; 95% CI, 1.38--2.55), MeIQx (OR, 2.25; 95% CI, 1.65--3.06), and PhIP (OR, 1.84; 95% CI, 1.35--2.50).Table 3Association between HAA intake and prostate cancerMean (SD)CasesControlsOR (95% CI)^a^Total HAAs (ng/day) Low tertile17.5 (7.1)1001311.00 Moderate tertile35.6 (5.3)1081241.14 (0.83--1.58) High tertile72.9 (29.2)143961.90 (1.40--2.59) Trend P^b^\< 0.001Total Trp-P-1 (ng/day) Low tertile0.44 (0.55)1041291.00 Moderate tertile2.9 (0.55)1041281.05 (0.76--1.45) High tertile7.2 (5.0)143941.92 (1.42--2.61) Trend P\< 0.001Total MeIQ (ng/day) Low tertile2.3 (0.93)1001311.00 Moderate tertile4.5 (0.57)1091231.18 (0.85--1.63) High tertile9.0 (3.7)142971.87 (1.38--2.55) Trend P\< 0.001Total MeIQx (ng/day)Low tertile2.4 (0.98)991321.00Moderate tertile4.9 (0.71)1021301.05 (0.76--1.46)High tertile9.9 (3.9)150892.25 (1.65--3.06)Trend P\< 0.001Total PhIP (ng/day) Low tertile10.5 (4.2)1021291.00 Moderate tertile21.5 (3.2)1061261.06 (0.77--1.48) High tertile44.7 (18.3)143961.84 (1.35--2.50) Trend P\< 0.001*BMI* body mass index; *OR* oratio; *95% CI* 95% confidence interval; *HAA* heterocyclic aromatic amine; *Trp-P-1* 3-Amino-1, 4-dimethyl-5H-pyrido\[4, 3-b\]indole; *MeIQ* 2-Amino-3,4-dimethylimidazo\[4,5-f\]quinoline; *MeIQx* 2-Amino-3,8-dimethylimidazo\[4,5-f\]quinoxaline; *PhIP* 2-Amino-1-methyl-6-phenylimidazo\[4,5-b\]pyridine^a^ORs (95% CI) adjusted by conditional logistic regression for alcohol intake, smoking status, BMI, family history of prostate cancer, and total energy intake^b^ *P* value for Cochran--Armitage test for trend

Multivariate ORs for the *NAT2*-imputed phenotype and the *CYP1A1* and *CYP1A2* genotypes are shown in Table [4](#Tab4){ref-type="table"}. We found that the factors associated with a significantly increased risk of prostate cancer were the *NAT2* slow acetylator phenotype (OR, 1.65; 95% CI, 1.04--2.61), the *CYP1A1* GG genotype (OR, 1.76; 95% CI, 1.08--2.87), the *CYP1A1* GA + GG genotype (OR, 1.27; 95% CI, 1.02--1.59), the *CYP1A2* CA genotype (OR, 1.43; 95% CI, 1.01--2.03), the *CYP1A2* AA genotype (OR, 1.44; 95% CI, 1.00--2.06), and the *CYP1A2* CA + AA genotype (OR, 1.43; 95% CI, 1.03--2.00).Table 4Association between *NAT2*-imputed phenotype, *CYP1A1* and *CYP1A2* genotype, and prostate cancerCasesControls*P*OR (95% CI)^a^*NAT2*-imputed phenotype Rapid acetylator2062121.00 Intermediate acetylator1181210.691.05 (0.83--1.32) Slow acetylator27180.0341.65 (1.04--2.61)*CYP1A1* AA2072321.00 GA1191050.121.20 (0.95--1.52) GG25140.0231.76 (1.08--2.87) GA + GG1441190.0341.27 (1.02--1.59)*CYP1A2* CC34471.00 CA1771710.0451.43 (1.01--2.03) AA1401330.0481.44 (1.00--2.06) CA + AA3173040.0351.43 (1.03--2.00)*BMI* body mass index, *OR* odds ratio, *CI* confidence interval^a^OR (95% CI) adjusted by conditional logistic regression for alcohol intake, smoking status, BMI, family history of prostate cancer, and total energy intake

Analyses of combinations between HAA intake and *NAT2*-imputed phenotype and *CYP1A1* and *CYP1A2* genotypes are shown in Table [5](#Tab5){ref-type="table"}. High HAA intake was associated with an increased risk of prostate cancer among each genotype and NAT-imputed phenotype, with the exception of the *CYP1A2* CC genotype (OR, 2.65; 95% CI, 0.97--7.29; *P* for interaction, 0.003). In addition, among high HAA intake individuals, the risk was indicated by the phenotypes or genotypes, which were suggested from the result of Table [4](#Tab4){ref-type="table"}. *NAT2* slow acetylator phenotype, *CYP1A1* GA + GG, and *CYP1A2* CA + AA had higher OR than other paired phenotypes or genotypes as follows: the *NAT2* slow acetylator phenotype (OR, 5.29; 95% CI, 2.37--11.80; *P* for interaction, 0.004) was higher than the rapid or intermediate acetylator phenotype (OR, 1.85; 95% CI, 1.34--2.56); the *CYP1A1* GA + GG genotype (OR, 2.86; 95% CI, 1.83--4.47) was higher than the AA genotype (OR, 2.41; 95% CI, 1.61--3.63); and the *CYP1A2* CA + AA genotype (OR, 4.01; 95% CI, 1.60--10.05) was higher than the CC genotype (OR, 2.65; 95% CI 0.97--7.29) even though the CC genotype OR is not statistically significant. Among individuals from the *CYP1A1* GA + GG genotype group (*P* for interaction, \< 0.001), we found there was an association between increased risk of prostate cancer and all three HAA intake groups specifically low (OR, 2.05; 95% CI, 1.19--3.63), intermediate (OR, 1.72; 95% CI, 1.07--2.76), and high (OR, 2.86; 95% CI, 1.83--4.47).Table 5Prostate cancer risk and HAA intake stratified by *NAT2*-imputed phenotype and *CYP1A1* and *CYP1A2* genotypeHAA intakeLowModerateHigh*P* ~interaction~*NAT2*-imputed phenotype Rapid or intermediate acetylator Cases/Controls92/124100/116132/93 OR (95% CI)^a^1.001.17 (0.84--1.65)1.85 (1.34--2.56) Slow acetylator Cases/Controls8/78/811/3 OR (95% CI)1.43 (0.50--4.12)1.21 (0.56--2.60)5.29 (2.37--11.80)0.004*CYP1A1* AA  Cases/controls51/8768/8288/63  OR (95% CI)1.001.46 (0.95--2.24)2.41 (1.61--3.63) GA + GG  Cases/controls49/4440/4255/33  OR (95% CI)2.05 (1.19--3.63)1.72 (1.07--2.76)2.86 (1.83--4.47)\< 0.001*CYP1A2* CC  Cases/controls7/1714/1713/13  OR (95% CI)1.002.05 (0.73--5.77)2.65 (0.97--7.29) CA + AA  Cases/controls93/11494/107130/83 OR (95% CI)2.17 (0.85--5.59)2.34 (0.93--5.92)4.01 (1.60--10.05)0.003*BMI* body mass index, *OR* odds ratio, *CI* confidence interval, *HAA* heterocyclic aromatic amine^a^OR (95% CI) adjusted by conditional logistic regression for alcohol intake, smoking status, BMI, family history of prostate cancer, and total energy intake

Discussion {#Sec9}
==========

This is the first national study which investigates the association between dietary HAA intake by using FFQ for estimate the amount of HAA, HAA-metabolic polymorphisms, and prostate cancer risk in Japanese people. We found that a high HAA intake was significantly associated with an increased risk of prostate cancer (Table [3](#Tab3){ref-type="table"}), and the *NAT2* slow acetylator phenotype, the *CYP1A1* GG and GA + GG genotypes, and the *CYP1A2* CA, AA, and CA + AA genotypes were associated with an increased prostate cancer risk in our affected cohort with compared with the controls (Table [4](#Tab4){ref-type="table"}). In addition, the *CYP1A1* GA + GG genotype was associated with prostate cancer in low, moderate, and high HAA intake groups (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). These results support our hypothesis that high HAA intake is a risk factor of prostate cancer, and the degree of risk is influenced by polymorphisms in genes encoding HAA metabolic enzymes.

Previous studies have shown confounding results on whether there is an association between HAA intake and prostate cancer risk \[[@CR1], [@CR3], [@CR17], [@CR18]\]. In Japanese, several studies specifically investigated the risk of only meat and fish intake to prostate cancer \[[@CR21], [@CR22]\], but no prior study investigated the association between dietary HAAs and prostate cancer risk in a Japanese population. The main reason for the absence of such a study is because of the difficulty in assessing dietary HAA intake. The HAA composition of cooked meat and fish varies depending on the cooking method and meat type \[[@CR19], [@CR20]\]. In addition, typical elderly Japanese intake more fish than meat, and they tend to prefer chopping and stir-frying meat than grilling \[[@CR23], [@CR24]\]. Furthermore, foods that contribute to HAA intake differ by country \[[@CR25]\] and, therefore, dietary assessment tools for HAA intake should be tailored specifically for the population being studied. In this study, we used a validated assessment FFQ to assess dietary HAAs in our Japanese cohorts \[[@CR25], [@CR37], [@CR38]\], and we found that high HAA intake was associated with an increased risk of prostate cancer as follows: total HAA intake (OR, 1.90; 95% CI, 1.40--2.59), Trp-P-1 (OR, 1.92; 95% CI, 1.42--2.61), MeIQ (OR, 1.87; 95% CI, 1.38--2.55), MeIQx (OR, 2.25; 95% CI, 1.65--3.06), and PhIP (OR, 1.84; 95% CI, 1.35--2.50) (Table [3](#Tab3){ref-type="table"}). In previous studies, which were not Japanese cohort research, no data or significant associations in prostate cancer were observed for dietary Trp-P-1, MeIQ, or MeIQx \[[@CR3], [@CR4], [@CR43], [@CR44]\]. A statistically significant association between PhIP and prostate cancer risk was observed in one study \[[@CR44]\]; however, null or opposed associations were reported in another study \[[@CR3], [@CR4], [@CR45]\]. Thus, the present study is the first to report an association between dietary HAA intake and prostate cancer in a Japanese cohort, and it is epidemiologically plausible that high HAA intake is a risk factor of prostate cancer in Japan.

Regarding HAA metabolism, *NAT2* is a phase II enzyme that detoxifies HAA carcinogens, is expressed predominantly in the liver, and is highly polymorphic in humans \[[@CR13]\]. It was observed that the frequency of *NAT2* genotypes varies by population \[[@CR27]\]. A previous study showed that the *NAT2* slow acetylator phenotype presents decreased enzymatic activity compared with the activity levels of the rapid or intermediate genotypes \[[@CR46]\]. As a result, the *NAT2* slow acetylator phenotype is considered to reduce hepatic N-acetylation (detoxification) and increase the chance of hepatic N-hydroxylation (activation) \[[@CR31]\]. One meta-analysis showed that there was no evidence of an association between *NAT2* polymorphisms and prostate cancer in a combined analysis, but there was an association in Asian populations based on racial subgroup analysis \[[@CR47]\]. In our study, we found that the *NAT2* slow acetylator phenotype was associated with an increased risk of prostate cancer (OR, 1.65; 95% CI, 1.04--2.61) (Table [4](#Tab4){ref-type="table"}) and that the *NAT2* slow acetylator phenotype (OR, 5.29; 95% CI, 2.37--11.80; *P* for interaction, 0.004) was higher than rapid or intermediate acetylator phenotypes (OR, 1.85; 95% CI, 1.34--2.56) among individuals with high HAA intake (Table [5](#Tab5){ref-type="table"}). We posit that this finding indicates that individuals with the *NAT2* slow acetylator phenotype have reduced detoxification of HAA carcinogens and increased chance of carcinogen activation, compared with other acetylator phenotypes in individuals with prostate cancer. Although *NAT2* is expressed in prostate epithelium and the liver \[[@CR13]\], our results suggest that the expression of the *NAT2* phenotype in the liver has greater metabolic influence on HAA carcinogens of prostate cancer than its expression in the prostate.

*CYP1A1* is a member of the phase I cytochrome P450 family, which is highly active in the liver, acting on the metabolic activation of HAAs \[[@CR28]\]. Similar to *NAT2*, *CYP1A1* mRNA is also expressed in prostate tissue \[[@CR48]--[@CR50]\]. *CYP1A1* in individuals harboring the mutant G allele (GA or GG genotype) in exon 7, which substitutes valine for isoleucine, has a higher catalytic activity compared to that found in individuals who are homozygous AA \[[@CR51]\]. Findings from a previous study suggested that the *CYP1A1* GA + GG genotype confers susceptibility to prostate cancer and that individuals with the *CYP1A1* GG genotype have a significantly increased risk \[[@CR29], [@CR52]\]. Further, a meta-analysis study showed using subgroup analysis that the *CYP1A1* GA + GG genotypes were associated with prostate cancer risk in Asians \[[@CR53]\]. Similarly, in our study, we found that the *CYP1A1* GA + GG genotypes were associated with prostate cancer risk (OR, 1.27; 95% CI, 1.02--1.59) (Table [4](#Tab4){ref-type="table"}), and this evidence of an association was observed not only in the high HAA intake group (OR, 2.86; 95% CI, 1.83--4.47), but also in even the low (OR, 2.05; 95% CI, 1.19--3.63) and moderate (OR, 1.72; 95% CI, 1.07--2.76) HAA intake groups (Table [5](#Tab5){ref-type="table"}). These findings provide further support that there is a relationship between *CYP1A1* GA + GG genotypes and an enhanced effect on HAA carcinogens in prostate cancer. The second possibility is that this *CYP1A1* polymorphism is an independent risk factor for prostate cancer.

Similar to *CYP1A1*, *CYP1A2* is a phase I metabolizing enzyme that plays a prominent role in the activation of HAA carcinogens \[[@CR28]\], and it is also expressed in prostate tissue \[[@CR49], [@CR50]\]. *CYP1A2* in individuals with the A allele (CA or AA genotype) has a higher enzymatic activity compared to that found in individuals who are homozygous CC \[[@CR54]\]. A previous study showed that the *CYP1A2* CC genotype may be associated with risk of prostate cancer but the finding was not statistically significant \[[@CR29]\]. It is unclear how reduced *CYP1A2* activity contributes to an increased risk of prostate cancer. Nevertheless, in contrast to past findings, we found that the *CYP1A2* AA, CA, and CA + AA genotypes were associated with an increased risk of prostate cancer (Table [4](#Tab4){ref-type="table"}) and that the *CYP1A2* CA + AA genotype (OR, 4.01; 95% CI, 1.60--10.05; *P* for interaction, 0.003) was higher than the CC genotype (OR, 2.65; 95% CI, 0.97--7.29) among individuals with high HAA intake, even though the CC genotype OR is not statistically significant, we still can find the trend (Table [5](#Tab5){ref-type="table"}). These findings support that *CYP1A2*-induced higher activation of HAAs in the liver and/or prostate is important for increased risk of prostate cancer. However, considering its opposition to past findings, future studies testing larger Japanese cohorts are warranted to replicate these findings, and further research is needed to understand how *CYP1A2* polymorphisms metabolically influence HAA carcinogens.

There are several limitations of our study. First, an inherent challenge in case control studies is to minimize the influence of selection and information bias (e.g., recall bias), although in our study, the controls were not only population- and age-matched but also were recruited from the same city area (metropolitan Tokyo). Second, although we analyzed each individual polymorphism, we did not investigate the putative effects of different polymorphism combinations because of the modest sample size of our cohorts. Third, because we did not directly determine HAA metabolic reactions in prostate tissue or other organs such as the liver, the effects or contributions of other metabolic pathways cannot be excluded. Nevertheless, to our knowledge, this is the first study to investigate the relationship between HAA intake, functional gene polymorphisms related to the HAA metabolic pathway, and prostate cancer risk in Japanese men.

Conclusions {#Sec10}
===========

In summary, we performed a secondary data analysis of an observational case control study to determine the relationships between HAA intake and specific polymorphisms in three genes to prostate cancer in Japanese men. Based on our analysis, we found that high HAA intake was significantly associated with increased prostate cancer risk. In addition, we found that the *NAT2* slow acetylator phenotype, the *CYP1A1* GA + GG genotype, and the *CYP1A2* CA + AA genotype were associated with increased prostate cancer risk. In particular, the *CYP1A1* GA + GG genotype had increased risk even in the low and moderate HAA intake groups. These findings indicate that high HAA intake is a risk factor of prostate cancer in Japanese men, and that the genotypes of *NAT2*, *CYP1A1*, and *CYP1A2* may affect the degree of cancer risk via changes in HAA-metabolizing enzymes.

4,8-DiMelQx

:   2-Amino-3, 4, 8-trimethylimidazo\[4, 5-f\]quinoxaline

7,8-DiMelQx

:   2-Amino-3, 7, 8-trimethylimidazo\[4, 5-f\]quinoxaline

95% CI

:   95% Confidence interval

BMI

:   Body mass index

CYP

:   Cytochrome P450

FFQ

:   Food frequency questionnaire

HAA

:   Heterocyclic aromatic amine

IQ

:   2-Amino-3-methylimidazo\[4, 5-f\]quinoline

MeIQ

:   2-Amino-3, 4-dimethylimidazo\[4, 5-f\]quinoline

MeIQx

:   2-Amino-3, 8-dimethylimidazo\[4, 5-f\]quinoxaline

NaCl

:   Sodium chloride

*NAT1*

:   *N*-acetyltransferase 1

*NAT2*

:   *N*-acetyltransferase 2

OR

:   Odds ratio

PhIP

:   2-Amino-1-methyl- 6-phenylimidazo\[4,5-b\]pyridine

SD

:   Standard deviation

SNP

:   Single nucleotide polymorphism

Trp-P-1

:   3-Amino-1, 4-dimethyl-5H-pyrido\[4, 3-b\]indole

UTR

:   Untranslated region

We thank all the staff of the Mitsui Memorial Hospital and the Jikei University School of Medicine Hospital for their outstanding support. We also thank Dr. Kemmyo Sugiyama MD, Ph.D., of Toshoku University for his critical advice on our statistical analysis and Dr. Nahoko Harada RN, Ph.D., of the University of Miyazaki for her advice on the entire project.

Funding {#FPar1}
=======

This study received no specific grant from any funding agency in the public, commercial, or non-profit sectors.

Availability of data and materials {#FPar2}
==================================

The datasets generated and/or analyzed during the current study are not publicly available due to ethical considerations but are available from the corresponding author on reasonable request.

MK designed the study, performed the genotyping and statistical analyses, interpreted the data, and drafted the manuscript. XL assisted with the design of the study and checked the manuscript. MI and TK were involved in data collection, assisted with the design of the study, and checked the manuscript. YY participated in the study concept and checked the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

The study protocol received ethics approval from the institutional review board of Faculty of Life Sciences, Kumamoto University (Kumamoto, Japan), on June 10, 2016 (approval number 209). Written informed consent was obtained from all participants by the return of the questionnaires. Participants had the option not to respond to any part of the questionnaire and could discontinue participation at any point.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that no competing interests exist.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
